Risk Factors and Treatment Outcomes in Metastatic Prostate Cancer with Brain Metastases
Authors:
- Vincent E XuVXVincent E Xu
- Jeffrey WangJWJeffrey Wang
- Rachel C BernardoRBRachel C Bernardo
- Michelle WangMWMichelle Wang
- Michael J WhalenMWMichael J Whalen
- Maneesh JainMJManeesh Jain
- Fayez EstephanFEFayez Estephan
- Lekhaj DaggubatiLDLekhaj Daggubati
- Sharad GoyalSGSharad Goyal
- Yuan James RaoYRYuan James Rao
- 18 June 2026
- journal article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (7)
Abstract
No abstract availableThis publication has 79 references indexed in Scilit:
- Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasisThe Prostate, 2023
- Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancerCancer, 2021
- Systemic Anti–PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal FluidJAMA Oncology, 2020
- Androgen receptor signaling‐targeted therapy and taxane chemotherapy induce visceral metastasis in castration‐resistant prostate cancerThe Prostate, 2020
- Comparison of Local Control of Brain Metastases With Stereotactic Radiosurgery vs Surgical ResectionJAMA Oncology, 2018
- Distribution of metastatic sites in patients with prostate cancer: A population‐based analysisThe Prostate, 2013
- Should extrapulmonary small cell cancer be managed like small cell lung cancer?Cancer, 2010
- Brain metastasis from prostate carcinomaCancer, 2003
- A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasisCancer, 1996
- Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgeryAnnals of Neurology, 1993